Seelos therapeutics announces mid-year 2021 business and clinical update

New york, aug. 9, 2021 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced its mid-year 2021 business and clinical update. "in the first half of 2021, the seelos team continued to execute at a very high level.

SEEL Ratings Summary

SEEL Quant Ranking